Tetra Pharm Technologies

Tetra Pharm Technologies is a private, Copenhagen-based biopharma founded in 2017/2018 with a dual business model. Its core focus is an internal R&D pipeline targeting high-need CNS indications like chronic pain, Alzheimer's, obesity (with a neurological focus), and mental health disorders. Concurrently, it commercializes its expertise through a CDMO division, offering tailored development and manufacturing services leveraging its proprietary ZYNDIKATE® drug delivery platform. The company is led by a seasoned management team with deep experience from major pharmaceutical firms like Novo Nordisk, Lundbeck, and Biogen.

Proprietary drug delivery technology platform named ZYNDIKATE®, designed to enhance drug delivery, particularly for central nervous system (CNS) targets. It underpins both internal pipeline development and external CDMO services.

In therapeutics, TETRAPHARM competes with large pharma and numerous biotechs in crowded CNS spaces like Alzheimer's and pain. As a CDMO, it competes with larger, established CDMOs and must differentiate itself on its niche expertise in CNS-targeted drug delivery via the ZYNDIKATE® platform.